These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 19223284

  • 1. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
    Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, Connors L, Kaur A, Curtis S, Laine L, Cannon CP.
    Rheumatology (Oxford); 2009 Apr; 48(4):425-32. PubMed ID: 19223284
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
    Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, Simpson R, Curtis S.
    Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 6. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee.
    Lancet; 2007 Feb 10; 369(9560):465-73. PubMed ID: 17292766
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
    Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP.
    Gastroenterology; 2008 Nov 10; 135(5):1517-25. PubMed ID: 18823986
    [Abstract] [Full Text] [Related]

  • 9. Perioperative blood loss and gastrointestinal tolerability of etoricoxib and diclofenac in total hip arthroplasty (ETO-DIC study): a single-center, prospective double-blinded randomized controlled trial.
    Winkler SH, Barta S, Kehl V, Schröter C, Wagner F, Grifka J, Springorum HR, Craiovan B.
    Curr Med Res Opin; 2016 Nov 10; 32(1):37-47. PubMed ID: 26414653
    [Abstract] [Full Text] [Related]

  • 10. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec 10; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 11. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)].
    Alekseeva LI.
    Ter Arkh; 2010 Dec 10; 82(8):57-62. PubMed ID: 20873248
    [Abstract] [Full Text] [Related]

  • 12. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
    Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CP.
    Cardiovasc Ther; 2012 Dec 10; 30(6):342-50. PubMed ID: 21884017
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis.
    Zacher J, Feldman D, Gerli R, Scott D, Hou SM, Uebelhart D, Rodger IW, Ozturk ZE, etoricoxib OA study group.
    Curr Med Res Opin; 2003 Dec 10; 19(8):725-36. PubMed ID: 14687444
    [Abstract] [Full Text] [Related]

  • 16. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S.
    Curr Med Res Opin; 2004 Dec 10; 20(12):1899-908. PubMed ID: 15701208
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.
    Rheumatology (Oxford); 2007 Mar 10; 46(3):496-507. PubMed ID: 16936327
    [Abstract] [Full Text] [Related]

  • 18. [By what means does the rheumatic patient with gastrointestinal risks fare best?].
    Einecke D.
    MMW Fortschr Med; 2007 Mar 08; 149(10):18. PubMed ID: 17408040
    [No Abstract] [Full Text] [Related]

  • 19. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
    Feng X, Tian M, Zhang W, Mei H.
    PLoS One; 2018 Mar 08; 13(1):e0190798. PubMed ID: 29320568
    [Abstract] [Full Text] [Related]

  • 20. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 08; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.